Compare FDMT & ONT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDMT | ONT |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 695.3M | 600.3M |
| IPO Year | 2019 | 2020 |
| Metric | FDMT | ONT |
|---|---|---|
| Price | $10.38 | $19.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $31.71 | N/A |
| AVG Volume (30 Days) | ★ 794.2K | 490.7K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 230194.60 | N/A |
| 52 Week Low | $4.27 | $15.95 |
| 52 Week High | $14.00 | $22.50 |
| Indicator | FDMT | ONT |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 58.18 |
| Support Level | $9.71 | $19.68 |
| Resistance Level | $10.50 | $22.10 |
| Average True Range (ATR) | 0.79 | 1.10 |
| MACD | -0.30 | -0.30 |
| Stochastic Oscillator | 10.76 | 38.71 |
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).